Skip to main content

Table 2 Perioperative outcomes of the four cohorts

From: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?

ValueHCC (n = 9)CCa (n = 4)GBC (n = 3)PCa (n = 1)p value
PCI12 [6–16]7 [4–13]21 [7–27]10 [10]0.538
Number of organs resected2 [1–5]2 [1–5]4 [4–9]6 [6]0.626
CC score    0.668
 CC-0/17 (78)4 (100)1 (33)1 (100) 
 CC-2/32 (22)0 (0)2 (67)0 (0) 
EBL, cc500 [100–700]450 [225–750]600 [200–2000]150 [150]0.780
OR time, min305 [250–388]304 [231–327]345 [302–385]358 [358]0.795
LOS, days5 [5–9]6 [6–8]7 [5–8]3 [3]0.833
ICU stay4 (44)0 (0)1 (33)0 (0)0.430
Perioperative major morbidity1 (11)0 (0)1 (33)0 (0)0.471
Perioperative mortality1 (11)0 (0)0 (0)0 (0)0.815
Adjuvant chemotherapy7 (78)4 (100)3 (100)1 (100)0.569
Follow-up time, months23 [3–42]19 [15–21]2 [0–13]15 [15]0.493
  1. HCC hepatocellular carcinoma, CCa cholangiocarcinoma, GBC gallbladder cancer, PCa pancreatic cancer, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy, PCI peritoneal cancer index, CC completeness of cytoreduction, EBL estimated blood loss, OR operating room, LOS length of stay, ICU intensive care unit